Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors

Background The grading of pancreatic neuroendocrine neoplasms (PanNENs) is associated with the choice of treatment strategy. The aim of this study is to identify the magnetic resonance imaging (MRI) features in differentiating pancreatic neuroendocrine tumors (PanNETs) grade 1/2 (G1/G2) and pancreatic neuroendocrine carcinoma grade 3 (PanNEC G3). Patients and methods A total of 59 patients with histologically proven PanNENs and who underwent pretreatment MRI were retrospectively analyzed. Tumor location, size, boundary, cystic or solid appearance, enhancement degree, pancreatic duct dilatation, metastases and MRI signal were evaluated. Apparent diffusion coefficients (ADCs) were measured on ADC maps. Receiver operating characteristic curve was used to determine the cut off values and the sensitivity and specificity of prediction. Spearman correlation and logistic regression analysis were adopted to identify the association between MRI features and pathological parameters. Results A total of 47 lesions were PanNETs G1/G2 and 12 lesions were PanNEC G3. G1/G2 tumors were more common with well-circumscribed border compared with PanNEC G3. Ill- defined boundary, big size, necrosis, low-moderate enhancement, pancreatic duct dilatation, metastases and high diffusion-weighted imaging (DWI) intensity were more common in PanNEC G3 than in PanNETs G1/G2. The ADC values of PanNEC G3 were also significantly lower compared with the PanNETs G1/G2 and normal pancreatic parenchyma. The cut off value of ADC was 0.95×10−3 mm2/s for differentiating PanNEC G3 from PanNETs G1/G2 with 72.3% sensitivity and 91.6% specificity, respectively. Ki-67 index and mitosis count positively correlated with tumor size, pancreatic duct dilatation and metastases (P<0.05) and negatively correlated with ADC values (P<0.01), respectively. Regression analysis further showed that metastases and ADC value were associated with PanNENs grade. Conclusion Metastases and ADC value may have potential for differentiating PanNEC G3 from PanNETs G1/G2.

[1]  Toshihiro Kumabe,et al.  Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. , 2006, Radiology.

[2]  I. Steffen,et al.  Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors. , 2013, European journal of radiology.

[3]  T. Yoshiura,et al.  Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. , 2015, European journal of radiology.

[4]  B. Seifert,et al.  Diffusion-weighted MR imaging of upper abdominal organs: field strength and intervendor variability of apparent diffusion coefficients. , 2014, Radiology.

[5]  Kyoung-Mee Kim,et al.  Proposal for a Standardized Pathology Report of Gastroenteropancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters , 2013, Korean journal of pathology.

[6]  K. Nakao,et al.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan , 2010, Journal of Gastroenterology.

[7]  T. Baère,et al.  Endocrine pancreatic tumours: which are the most useful MRI sequences? , 2010, European Radiology.

[8]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[9]  P. Herscovitch,et al.  Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. H. Kim,et al.  Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour , 2015, European Radiology.

[11]  Jérôme Cros,et al.  Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging , 2017, European Radiology.

[12]  N. Funel,et al.  Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours , 2015, European Radiology.

[13]  Tonsok Kim,et al.  Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. , 2015, Surgery.

[14]  Andrew J. Taylor,et al.  Multimodality imaging of pancreatic and biliary congenital anomalies. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[15]  Yi Wang,et al.  Diffusion‐weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics , 2011, Journal of magnetic resonance imaging : JMRI.

[16]  T. Metens,et al.  Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. , 2012, European journal of radiology.

[17]  B. Centeno,et al.  Neuroendocrine Neoplasms of the Pancreas , 2016 .

[18]  K. Ohtomo,et al.  Atypical exocrine and endocrine pancreatic tumors (anaplastic, small cell, and giant cell types): CT and pathologic features in 14 patients , 2000, Abdominal Imaging.

[19]  Joon Koo Han,et al.  Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment--a preliminary study. , 2013, Radiology.

[20]  B. Wiedenmann,et al.  Neuroendocrine neoplasms of the gut and pancreas: new insights , 2012, Nature Reviews Endocrinology.

[21]  D. Choi,et al.  The value of gadoxetic acid-enhanced and diffusion-weighted MRI for prediction of grading of pancreatic neuroendocrine tumors , 2014, Acta radiologica.

[22]  A. Sundin,et al.  Recent developments in imaging of pancreatic neuroendocrine tumors , 2015, Annals of gastroenterology.

[23]  D. Planchard,et al.  Are G3 ENETS neuroendocrine neoplasms heterogeneous? , 2013, Endocrine-related cancer.

[24]  R. Jensen,et al.  Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan , 2016, Journal of Gastroenterology.

[25]  Yi Wang,et al.  Diffusion-weighted MR imaging of solid and cystic lesions of the pancreas. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[26]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[27]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[28]  J. Thiran,et al.  Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[29]  B. Choi,et al.  Staging accuracy of MR for pancreatic neuroendocrine tumor and imaging findings according to the tumor grade , 2013, Abdominal Imaging.

[30]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[31]  E. Kebebew,et al.  18F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippel–Lindau Disease , 2016, Annals of Surgical Oncology.

[32]  A. Scarpa,et al.  Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. , 2011, Surgery.

[33]  H. Ueno,et al.  Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma , 2015, Journal of hepato-biliary-pancreatic sciences.